Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cetuximabβ, Envolimab, and mFOLFOX6 for RAS/BRAF Wild-type MSS Metastatic Colorectal Cancer
NCT07000305Phase 2Not yet recruiting
- Start
- May 2025
- Primary completion
- May 2027
- Modality
- Nanobodies (VHH), Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of KL-140, envafolimab in colorectal cancer (metastatic) (mCRC). Planned start May 2025; status: not yet recruiting.
02
Drugs
KL-140envafolimab
03
Conditions
colorectal cancer (metastatic) (mCRC)
Beyond the preview
Go deeper on NCT07000305.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07000305.